The Effect of Captopril Added to Standard Chemotherapy Regimen Containing Capecitabine in the Prevention of Hand and Foot Syndrome in Patients with Colorectal Cancer

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Hematology and Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Resident, Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: This study aimed to evaluate the effect of captopril added to standard chemotherapy regimen containing capecitabine in the prevention of hand and foot syndrome in patients with colorectal cancer.Methods: In a clinical trial study, 66 patients with colorectal cancer under chemotherapy with capecitabine-containing regimens were distributed in two groups of 33. The first group received 50 mg of captopril daily and the control group, placebo with a similar dose from one week before commencement of chemotherapy to the end of third course of treatment. Patients in two groups were evaluated for the onset of hand and foot syndrome three and six weeks after starting chemotherapy, and four weeks after the end of third course of chemotherapy.Findings: At the end of our study, 2 patients (6.1%) in the intervention group and 8 patients (24.2%) in the control group suffered from hand and foot syndrome (P = 0.039). Six weeks after the start of treatment, the prevalence of hand and foot syndrome in intervention and control groups was 3 (9.1%) and 5 (15.2%) (P = 0.45), and 2 (6.1%) and 8 (24.2%) cases four weeks after the completion of the three courses of chemotherapy, respectively (P = 0.039).Conclusion: Administration of captopril in patients undergoing chemotherapy with capecitabine-containing regimen reduced symptoms of hand and foot syndrome four weeks after the completion of the three courses of chemotherapy. According to the similarity of the pathogenesis of hand and foot syndrome with other vascular disorders, administration of captopril seems to reduce the symptoms of hand and foot syndrome.

Keywords

References

  1. Amori N, Aghajani M, Asgarian FS, Jazayeri M. Epidemiology and trend of common cancers in Iran (2004-2008). Eur J Cancer Care (Engl) 2017; 26(5).
  2. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's cancer: Principles and practice of oncology. 10th ed. LWW; Philadelphia, PA: Lippincott Williams and Wilkins; 2015.
  3. Emami MH, Fatemi AM, Farajzadegan Z, Movahed Abtahi SM. Epidemiology of colorectal cancer In Isfahan Province. Govaresh 2005; 10(3): 134-9. [In Persian].
  4. Rahimi Pordanjani S, Baeradeh N, Lotfi MH, Pourmohammadi B. Epidemiology of colorectal cancer: incidence, mortality, survival rates and risk factors. Razi J Med Sci 2016; 23(144): 41-50. [In Persian].
  5. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12(3): 131-41.
  6. Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, et al. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol 2017; 49: 81-8.
  7. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101(6): 798-9.
  8. Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, et al. Possible pathways of Capecitabine-induced hand-foot syndrome. Chem Res Toxicol 2016; 29(10): 1591-601.
  9. Saif MW. Capecitabine and handÇôfoot syndrome. Expert Opinion on Drug Safety 2011; 10(2): 159-69.
  10. Lorusso D, Di SA, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007; 18(7): 1159-64.
  11. Naito M, Yamamoto T, Hara S, Shimamoto C, Miwa Y. Hemoglobin Value Is the Most Important factor in the development of hand-foot syndrome under the Capecitabine regimen. Chemotherapy 2017; 62(1): 23-9.
  12. Kanbayashi Y, Hosokawa T, Yasui K, Hongo F, Yamaguchi K, Moriguchi M, et al. Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis. Am J Health Syst Pharm 2016; 73(1): e18-e23.
  13. Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 2016; 15(12): 1625-33.
  14. Lal HS. Hand and foot syndrome secondary to capecitabine. Indian J Dermatol Venereol Leprol 2014; 80(5): 427-30.
  15. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1(4): 225-34.
  16. Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989; 111(8): 688-9.
  17. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8(1): 57-63.
  18. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13(11): 2851-5.
  19. Chin SF, Tchen N, Oza AM, Moore MJ, Warr D, Siu LL. Use of "Bag Balm " as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents [abstract 1632]. Proc Am Soc Clin Oncol 2001; 20: 409a.
  20. Yamagiwa K, Shigematsu T, Takeda K, Shirai M, Amemori K, Sunda K, et al. Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy. Gan To Kagaku Ryoho 2013; 40(Suppl 2): 161-3. Japanese
  21. Zhang JZ, Xi X, Gao L, Kern TS. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 2007; 32(10): 883-9.
  22. Coppola G, Romano G, Corrado E, Grisanti RM, Novo S. Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag 2008; 4(6): 1179-87.
  23. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113(11): e463-e654.
  24. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25(1): 17-24.
  25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145-53.
Journal of Isfahan Medical School
Volume 37, Issue 535 - Serial Number 535
May and June 2019
Pages 824-831

Files

History

  • Receive Date: 18 May 2019
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics